Ondine Biomedical INC.
Ondine Biomedical Inc. (LON:OBI) is a Canadian life sciences company developing and commercialising light-activated antimicrobial (photodisinfection, aPDT) therapies to prevent and treat healthcare-associated infections, including those caused by multidrug-resistant microbes, without contributing to antibiotic resistance. Its lead commercial product, Steriwave, is a nasal photodisinfection device used mainly for presurgical infection prevention, sold alongside a pipeline of additional indications (burns, chronic wounds, ICU, VAP, CLABSI, CAUTI). The Company's central 2025 priority was completing the pivotal U.S. LANTERN Phase 3 trial ahead of a planned FDA submission.
10.0c at close on 21 Oct 2026 · 6 reported years, FY2020–FY2025
| Line | FY2020locked | FY2021locked | FY2022locked | FY202312/23 | FY202412/24 | FY202512/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Gross profit | |||||||
| Operating profit | |||||||
| Net finance cost | |||||||
| Profit before tax | |||||||
| Tax charge | |||||||
| Profit for the year | |||||||
| EBITDA | |||||||
| Basic EPS | |||||||
| Diluted EPS |
CAD millions, negatives in brackets. Per-share lines in cents. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
3 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.